Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.

Development of WRAIR’s Pan-Coronavirus Vaccine Shows Promise

Image of A vial of spike ferritin nanoparticle WRAIR's COVID-19 vaccine. A vial of spike ferritin nanoparticle (SpFN), WRAIR’s COVID-19 vaccine. Built on a ferritin platform, the vaccine offers a flexible approach to targeting multiple variants of the virus that causes COVID-19 and potentially other coronaviruses as well (Photo by: Mike Walters, Walter Reed Army Institute of Research).

A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.

Scientists in WRAIR's Emerging Infectious Diseases Branch (EIDB) developed the SpFN nanoparticle vaccine, based on a ferritin platform, as part of a forward-thinking "pan-SARS" strategy that aims to address the current pandemic and acts as a first line of defense against variants of concern and similar viruses that could emerge in the future.

"The accelerating emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variants, including most recently Omicron, underscore the continued need for next-generation preemptive vaccines that confer broad protection against coronavirus diseases," said Dr. Kayvon Modjarrad, director of the Emerging Infectious Diseases Branch at WRAIR, co-inventor of the vaccine and the Army lead for SpFN. "Our strategy has been to develop a 'pan-coronavirus' vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species."

Pre-clinical studies published today in Science Translational Medicine indicate that the SpFN vaccine protects non-human primates from disease caused by the original strain of SARS-CoV-2 and induces highly-potent and broadly-neutralizing antibody responses against major SARS-CoV-2 variants of concern including the SARS-CoV-1 virus that emerged in 2002.

SpFN entered Phase 1 human trials in April 2021. Early analyses, expected to conclude this month, will provide insights into whether SpFN's potency and breadth, as demonstrated in preclinical trials, will carry over into humans. The data will also allow researchers to compare SpFN's immune profile to that of other COVID-19 vaccines already authorized for emergency use.

"This vaccine stands out in the COVID-19 vaccine landscape," Modjarrad said. "The repetitive and ordered display of the coronavirus spike protein on a multi-faced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection."

WRAIR developed a secondary candidate vaccine, a SARS-CoV-2 Spike Receptor-Binding Domain Ferritin Nanoparticle (RFN) vaccine, which targets a smaller part of the coronavirus Spike protein than the SpFN vaccine. Results from a study, published recently in the Proceedings of the National Academy of Sciences, show that this vaccine potentially offers similar protection against an array of SARS-CoV-2 variants and SARS-CoV-1.

"The RFN vaccine candidate is more compact and has some natural advantages as we try to increase the immune response against multiple coronaviruses using a single vaccine platform, so it is still under consideration as part of our pan-coronavirus vaccine development pipeline," said Dr. Gordon Joyce, WRAIR structural biologist and vaccine co-inventor.

"The threat from COVID-19 continues as it evolves, and eventually there will be other emerging disease threats," said Dr. Nelson Michael, director of the Center for Infectious Diseases Research at WRAIR. "Our investment in developing a next generation vaccine is an important step towards getting ahead of COVID-19 and future disease threats."

You also may be interested in...

COVID-19 therapeutics support DOD pandemic response

Article Around MHS
2/11/2022
Military personnel getting COVID-29 doses ready

The U.S. Army Medical Materiel Agency is helping to protect the operational force by distributing several new therapeutic options that help to lessen the symptoms of mild-to-moderate cases of COVID-19 and keep Soldiers, their families and beneficiaries out of the hospital.

COVID-19 Health Action Response for Marines continues to study long-term effects of COVID-19 on Marines

Article Around MHS
2/10/2022
Medical military personnel talking to a patient

A team composed of U.S. Navy medical personnel and civilian technicians based out of the Naval Medical Research Center in Silver Spring, Maryland, assembled during the initial outbreak of COVID-19 to study the short and long-term effects that the virus has on Marines. 

Does CSM Gragg Have COVID-19?

Video
2/9/2022
Does CSM Gragg Have COVID-19?

CSM Gragg demonstrates how to use a COVID-19 at home rapid test.

Getting up-to-date on your COVID-19 vaccine

Article Around MHS
2/8/2022
Military personnel giving the COVID-19 vaccine

The U.S. Guard Coast is that we have vaccines to help prevent serious illness if you contract COVID-19.

VAXFacts TRICARE coverage Vaccine

Infographic
2/3/2022
Vax Fax COVID-19 Infographic

Will TRICARE cover the COVID-19 Vaccine? Yes. TRICARE offers the vaccine itself at no cost, but there may be a cost based on your plan for an office visit or if you require follow-on care.

Compromised Immune System

Infographic
2/3/2022
COVID-19 Infographic about Compromised Immune System

Do you have a compromised immune system? The CDC recommends you get an additional primary dose of the mRNA COVID-19 vaccine.

VaxFacts: Should I get a booster?

Infographic
2/3/2022
VaxFacts Infographic ab out the booster vaccine

Should I get a COVID-19 Booster Shot?

DOD COVID-19 Practice Management Guide Version 8

Technical Document
1/31/2022

This Practice Management Guide does not supersede DOD Policy. It is based upon the best information available at the time of publication. It is designed to provide information and assist decision making. It is not intended to define a standard of care and should not be construed as one. Neither should it be interpreted as prescribing an exclusive course of management. It was developed by experts in this field. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of this guideline is responsible for evaluating the appropriateness of applying it in the setting of any particular clinical situation. The Practice Management Guide is not intended to represent TRICARE policy. Further, inclusion of recommendations for specific testing and/or therapeutic interventions within this guide does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor.

Oregon National Guard surging to support hospitals again

Article Around MHS
1/27/2022
Oregon Army National Guard touring a hospital

Hundreds of Oregon National Guard members are increasing support of hospitals throughout the state in their second hospital relief mission during the COVID-19 pandemic.

Public Health nurses offer insights on living with COVID-19 now, looking into future

Article Around MHS
1/25/2022
The Challenges of Living with COVID

One of the more challenging jobs for any public health professional is dealing with unpredictability inherent in outbreaks like the current COVID-19 pandemic.

Do You Have COVID-19? Influenza? Or is it RSV? Here’s What to Look For

Article
1/24/2022
Military personnel preparing a COVID-19 test sample for processing

Knowing the symptoms of COVID-19/RSV/Flu will help your medical treatment

Medical Leaders Address COVID-19 Concerns During Family Forum

Article
1/21/2022
Navy Petty Officer 3rd Class Jemuel Macabali, from San Diego, Calif., gives the COVID-19 vaccine to staff at Camp Lemonnier, in Djibouti, Aug. 13, 2021.

Top health leaders talk about the recent spike in COVID-19 infections and the impact on the military community.

Navy Hospital Corpsman steps into the breach in the war on COVID-19

Article Around MHS
1/18/2022
Hospitalman Hector Conde standing in front of a immunization office's refrigeration

First responders and those fighting on the medical battleground have earned well-deserved recognition for their efforts.

Critically ill COVID Patient Delivers Baby While on Heart-Lung Bypass

Article
1/11/2022
Retired U.S. Marine Corps Gunnery Sgt. Carlos Hernandez and his wife, Ashley, take a family portrait with their six children. Ashley is BAMC’s first patient to give birth while on Extracorporeal Membrane Oxygenation.

Hernandez, a Marine Corps spouse and mother of five, is BAMC’s first patient to give birth while on Extracorporeal Membrane Oxygenation.

DHA Form 236: Pediatric (5-11 years) COVID-19 Vaccine Screening and Immunization Documentation, v10

Form/Template
1/7/2022

This form is used to determine if the COVID-19 vaccine can be administered to the pediatric patient. (Version 10, December 2022)

Page 4 of 25 , showing items 46 - 60
First < 1 2 3 4 5  ... > Last 
Refine your search
Last Updated: May 04, 2023
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery